ImportantSale or disposal
Emcure's subsidiary, Gennova, sold its mRNA business for 139.5 Cr cash via slump sale to Immunoscript Life Science.
Emcure Pharmaceuticals LimitedEMCURE · Filed with the exchange
This strategic move helps Gennova focus on core biotech products and biosimilars.
The divested mRNA unit contributed 64.71 Cr revenue and 132.63 Cr net worth in FY26.
No comments yet. Be the first.